Contact
searchSearch
HMP Global

Parkinson Disease Topic Center

FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Phase 3 TEMPO-1 Trial Reports Positive Results on Tavapadon for Parkinson Disease
10/09/2024
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational...
10/09/2024
Neurology
News
Parkinson Disease Risk Elevated in Patients With Upper GI Mucosal Damage
09/30/2024
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper...
09/30/2024
Neurology
Pop quiz written on a blackboard with white chalk
Quiz
Anxiety and Parkinson Disease Development in Older Adults
09/24/2024
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
09/24/2024
Neurology
A woman holds her forehead in pain with a migraine
News
No Link Found Between Migraine and Parkinson Disease, Contrary to Previous Findings
08/28/2024
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving...
08/28/2024
Neurology
An older woman sits alone
News
New-Onset Anxiety Increases PD Risk in Adults 50 and Older
08/27/2024
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson...
08/27/2024
Neurology
Dementia in PD May Occur Less Frequently Than Previously Thought
News
Dementia in PD May Occur Less Frequently Than Previously Thought
08/21/2024
Dementia occurrence in Parkinson disease (PD) may occur less frequently or take more time to develop than previous studies have shown, according to recent results from 2 ongoing prospective studies published in Neurology. 
Dementia occurrence in Parkinson disease (PD) may occur less frequently or take more time to develop than previous studies have shown, according to recent results from 2 ongoing prospective studies published in Neurology. 
Dementia occurrence in Parkinson...
08/21/2024
Neurology
acupuncture
News
Acupuncture Improves Sleep, Quality of Life in Patients With Parkinson Disease
07/08/2024
Sleep scores in patients with Parkinson disease (PD) improved a significant 29.65 points on the Parkinson Disease Sleep Scale after 4 weeks of acupuncture treatment, according to a study published in JAMA Network Open.
Sleep scores in patients with Parkinson disease (PD) improved a significant 29.65 points on the Parkinson Disease Sleep Scale after 4 weeks of acupuncture treatment, according to a study published in JAMA Network Open.
Sleep scores in patients with...
07/08/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
FDA Rejects Parkinson Drug Due to 3rd-Party Manufacturing Concerns
07/02/2024
The US Food and Drug Administration (FDA) rejected AbbVie’s ABBV-95 (foscarbidopa/foslevodopa) last week, raising concerns via complete response letter (CRL) regarding the inspection of a third-party manufacturer listed in the drug...
The US Food and Drug Administration (FDA) rejected AbbVie’s ABBV-95 (foscarbidopa/foslevodopa) last week, raising concerns via complete response letter (CRL) regarding the inspection of a third-party manufacturer listed in the drug...
The US Food and Drug...
07/02/2024
Neurology
Researchers Discover Novel DNA Methylation Patterns in Patients with PD
News
Researchers Discover Novel DNA Methylation Patterns in Patients With PD
05/13/2024
Alterations in DNA methylation patterns, discovered in the blood of patients with Parkinson disease (PD), have the potential to serve as an epigenetic biomarker for PD, according to study results published in the Annals of Neurology.
Alterations in DNA methylation patterns, discovered in the blood of patients with Parkinson disease (PD), have the potential to serve as an epigenetic biomarker for PD, according to study results published in the Annals of Neurology.
Alterations in DNA methylation...
05/13/2024
Neurology

News

FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
A person walks down a boarded path with sunlight and trees in the background
News
Phase 3 TEMPO-1 Trial Reports Positive Results on Tavapadon for Parkinson Disease
10/09/2024
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational...
10/09/2024
Neurology
News
Parkinson Disease Risk Elevated in Patients With Upper GI Mucosal Damage
09/30/2024
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper gastrointestinal mucosal damage is associated with a 76% increased risk of subsequent Parkinson disease (PD), according to a study published online in JAMA Network Open.
A history of upper...
09/30/2024
Neurology
A woman holds her forehead in pain with a migraine
News
No Link Found Between Migraine and Parkinson Disease, Contrary to Previous Findings
08/28/2024
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving female participants found no link between migraine and later Parkinson disease (PD) development. Findings from the study were published in Neurology.
A new cohort study involving...
08/28/2024
Neurology
An older woman sits alone
News
New-Onset Anxiety Increases PD Risk in Adults 50 and Older
08/27/2024
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson disease (PD) is doubled in adults 50 and older with new-onset anxiety compared with those without anxiety, according to a study published in the British Journal of General Practice.
The risk of developing Parkinson...
08/27/2024
Neurology
Dementia in PD May Occur Less Frequently Than Previously Thought
News
Dementia in PD May Occur Less Frequently Than Previously Thought
08/21/2024
Dementia occurrence in Parkinson disease (PD) may occur less frequently or take more time to develop than previous studies have shown, according to recent results from 2 ongoing prospective studies published in Neurology. 
Dementia occurrence in Parkinson disease (PD) may occur less frequently or take more time to develop than previous studies have shown, according to recent results from 2 ongoing prospective studies published in Neurology. 
Dementia occurrence in Parkinson...
08/21/2024
Neurology
acupuncture
News
Acupuncture Improves Sleep, Quality of Life in Patients With Parkinson Disease
07/08/2024
Sleep scores in patients with Parkinson disease (PD) improved a significant 29.65 points on the Parkinson Disease Sleep Scale after 4 weeks of acupuncture treatment, according to a study published in JAMA Network Open.
Sleep scores in patients with Parkinson disease (PD) improved a significant 29.65 points on the Parkinson Disease Sleep Scale after 4 weeks of acupuncture treatment, according to a study published in JAMA Network Open.
Sleep scores in patients with...
07/08/2024
Neurology
The US Food and Drug Administration headquarters sign.
News
FDA Rejects Parkinson Drug Due to 3rd-Party Manufacturing Concerns
07/02/2024
The US Food and Drug Administration (FDA) rejected AbbVie’s ABBV-95 (foscarbidopa/foslevodopa) last week, raising concerns via complete response letter (CRL) regarding the inspection of a third-party manufacturer listed in the drug...
The US Food and Drug Administration (FDA) rejected AbbVie’s ABBV-95 (foscarbidopa/foslevodopa) last week, raising concerns via complete response letter (CRL) regarding the inspection of a third-party manufacturer listed in the drug...
The US Food and Drug...
07/02/2024
Neurology
Researchers Discover Novel DNA Methylation Patterns in Patients with PD
News
Researchers Discover Novel DNA Methylation Patterns in Patients With PD
05/13/2024
Alterations in DNA methylation patterns, discovered in the blood of patients with Parkinson disease (PD), have the potential to serve as an epigenetic biomarker for PD, according to study results published in the Annals of Neurology.
Alterations in DNA methylation patterns, discovered in the blood of patients with Parkinson disease (PD), have the potential to serve as an epigenetic biomarker for PD, according to study results published in the Annals of Neurology.
Alterations in DNA methylation...
05/13/2024
Neurology
Brain with stethoscope and pills
News
Prasinezumab May Benefit Early-Stage Parkinson Patients With Rapid Progression
04/23/2024
Prasinezumab may ease motor worsening to a greater extent in patients with more rapidly progressing early-stage Parkinson disease (PD) than in other early-stage PD patients, according to an exploratory analysis.
Prasinezumab may ease motor worsening to a greater extent in patients with more rapidly progressing early-stage Parkinson disease (PD) than in other early-stage PD patients, according to an exploratory analysis.
Prasinezumab may ease motor...
04/23/2024
Neurology
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use